Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03905252 · ClinicalTrials.gov registry record

Biomarkers for Human Heart Failure

A clinical trial of CHF, sponsored by Mayo Clinic.

Completed
Registry status
535
Enrollment target
1
Study location

NCT03905252 is a study of CHF that has completed, run by Mayo Clinic. The registered enrollment target is 535 participants, above the 92-participant average among 5 other CHF trials with a reported enrollment target (482% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03905252, a study of CHF, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
535 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to establish the various ranges of proteins that can be assayed in the plasma and urine from hospitalized patients with all classes of heart failure and/or STEMI (ST-segment elevation myocardial infarction)/NSTEMI (Non-ST-segment elevation myocardial infarction), as well as history reviews.

Conditions Studied

Interventions

  • OTHER sample analysis

Study Locations (1)

Minnesota

  • Mayo Foundation - Rochester

Trial Details

FieldValue
Enrollment Target 535 participants
Start Date 2009-08
Est. Completion 2024-02

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT03905252

The ClinicalTrials.gov registry entry for NCT03905252 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 535 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 92-participant average among 5 other CHF trials with a reported enrollment target (482% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with CHF appearing as the primary indexed condition, and to 1 intervention - of which sample analysis is the first listed.

NCT03905252 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT03905252 about?

NCT03905252 is a clinical study titled "Biomarkers for Human Heart Failure". The purpose of this study is to establish the various ranges of proteins that can be assayed in the plasma and urine from hospitalized patients with all classes of heart failure and/or STEMI (ST-segment elevation myocardial infarction)/NSTEMI (Non-ST-segment elevation myocardial infarction), as well...

What is the current status of trial NCT03905252?

This trial is currently completed. The enrollment target is 535 participants. The study started on 2009-08. Estimated completion is 2024-02.

What conditions does trial NCT03905252 study?

This clinical trial studies the following conditions: CHF.

What interventions are being tested in trial NCT03905252?

The interventions under investigation include: sample analysis (OTHER).

Who is sponsoring clinical trial NCT03905252?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03905252 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for CHF

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.